Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Health Safety topic
No spam. Unsubscribe anytime.
Senate approves SB66 to tighten rules on compounded GLP‑1 weight‑loss drugs after floor amendments
Summary
The Colorado Senate on March 16 adopted SB66, a bill requiring compounded GLP‑1 weight‑loss medications to use FDA‑approved or FDA‑registered sources for ingredients, add clearer labeling, and give enforcement authority to the state Attorney General; floor amendment L008 (small‑batch and facility exemptions) passed and amendment L009 failed.
The Colorado Senate on March 16 adopted SB66, legislation aimed at regulating compounded GLP‑1 weight‑loss medications that are not FDA‑approved. Sponsor Senator Judah said the measure is focused on patient safety, requiring traceable, human‑grade ingredients and clear labeling and giving the Colorado Attorney General enforcement authority under the Colorado Consumer Protection Act.
Senator Judah, the bill sponsor, told colleagues the bill "is about patient and consumer protection," and walked through what the bill does and does not do. She said SB66 targets compounded GLP‑1 products whose ingredients may originate from non‑FDA‑registered suppliers and that the measure does not restrict legitimate compounding for pediatric dosing, hormone therapy or long‑term care. "This bill protects good actors who are already following the rules," she said.
On the floor, the Senate adopted amendment L008, which exempts very small‑batch compounding (the adopted language describes an exemption at or below 20 units) and carves out hospitals, long‑term care facilities, home‑care agencies, PACE programs and adult‑day facilities. Supporters said the exemption helps "the little guys" and preserves access for narrow medical needs; critics said a 20‑unit threshold is small compared with common prescriptions. Senator Bright noted that a typical weekly GLP‑1 prescription can require about 50 units and warned the 20‑unit exemption may not be sufficient.
Opponents and cautious supporters raised several concerns during debate. Senator Bright and others argued the bill could unintentionally penalize legitimate compounding pharmacies and questioned whether the Attorney General's office is the right enforcement agency. Senator Carson, who spoke repeatedly in favor of the bill, said the intention is to target bad actors whose ingredients come from unregulated sources and to ensure accurate labeling for consumers.
An amendment (L009) offered to broaden exemptions for practitioners and to protect those "in substantial compliance" with compounding standards was introduced and debated at length. Proponents said L009 would hold harmless legitimate practitioners; opponents argued its language was vague and could undercut the bill's enforcement. L009 failed on the floor.
Following debate and the failed L009, the Senate voted to adopt SB66 as amended. Supporters described the bill as a narrowly tailored consumer‑safety measure aimed at preventing contamination, mislabeling and other risks associated with unregulated compounded GLP‑1 products.
The bill text assigns primary enforcement under the Colorado Consumer Protection Act to the Attorney General's office and requires pharmacies subject to the law to demonstrate ingredient traceability and labeling. The measure includes exemptions for hospitals, certain facilities and small‑batch compounding as adopted in L008. The Senate adopted SB66 and advanced it consistent with Senate procedure.
What's next: SB66 was adopted by the Senate on March 16; the transcript records the bill's adoption on the floor. Further implementation details and any administrative rules will depend on follow‑up by state agencies or guidance from the Attorney General's office.
(Reporting notes: quotes and descriptions above are drawn from floor remarks by Senator Judah and floor debate as recorded in the March 16, 2026 Senate transcript.)
